Synthetic Oxytocin Shields Rats From Anxiety Caused by Social Bullying

Picture a rat, roughly 250 grams, dropped into the home cage of a much larger, territorial male. The resident lunges, pins, and dominates for 10 minutes before the intruder is allowed to retreat behind a wire mesh barrier. Two days later it happens again, with a different aggressor in a different cage. And again. And again. Four sessions over a week, each with an unfamiliar bully. By the end, the smaller rat is measurably more anxious, reluctant to venture into exposed spaces, its behaviour on standard laboratory tests shifted in ways that look a lot like the human experience of chronic social stress.

But what if you could inoculate against that anxiety before it took hold? A team at São Paulo State University (UNESP) in Brazil has shown that carbetocin, a synthetic cousin of oxytocin, does something like exactly that when given to rats before each defeat session. The treated animals didn’t become bolder or more reckless. They simply behaved as though the bullying had never happened.

“The dose used had no anxiolytic effect, i.e., it didn’t make the animal more courageous,” says Carlos Crestani, a professor at UNESP’s Faculty of Pharmaceutical Sciences who coordinated the study, published in Progress in Neurobiology. “What happened was that it behaved similarly to the animals in the control group, which didn’t undergo stress.” That distinction matters. Carbetocin wasn’t masking fear or pumping up confidence; it was preventing the stress from leaving its mark in the first place.

Oxytocin is sometimes called the love hormone, which is a bit reductive. It does promote social bonding and calmness, but its relationship with cortisol, the body’s primary stress molecule, runs deeper than a feel-good label suggests. The two systems operate in a sort of seesaw: cortisol primes fight-or-flight responses while oxytocin pushes toward calm and connection. What the UNESP group wanted to know was whether boosting the oxytocin side of that balance could protect against the emotional fallout of repeated social defeat, a question that, perhaps surprisingly, had not been properly tested in rats.

“Laboratory rats aren’t as territorial as mice,” says Lucas Canto de Souza, who carried out the work during his postdoctoral research at UNESP and is now at the University of Texas in Dallas. “Therefore, the study is unprecedented in demonstrating the effects of carbetocin in these animals, reinforcing its role in modulating anxiety.” Most social defeat research uses mice, where territorial aggression comes more naturally. Getting the model to work reliably in rats required pairing smaller Wistar intruders with much larger Long-Evans or Wistar Hannover residents, animals weighing up to 800 grams, housed with lactating females to ramp up their aggression.

The team tested three doses of carbetocin, injected 30 minutes before each defeat session. Only the highest dose, 1 milligram per kilogram, prevented the anxiety. They measured this using the elevated plus maze, a platform shaped like a cross with two open arms and two enclosed ones. Anxious rats stick to the enclosed arms; relaxed ones explore the open ones. Defeated rats treated with saline spent significantly less time in the open arms than unstressed controls. But the carbetocin-treated defeated rats? They explored as freely as animals that had never been bullied. “The drug didn’t make them more fearless, but rather acted preventively, mitigating the impact on anxiety-like behavior,” says Canto de Souza.

Then the results got more interesting. The researchers tried blocking the effect with two different oxytocin receptor antagonists, drugs that should shut down oxytocin signalling. One of them, atosiban, did block carbetocin’s protection at low doses, confirming the effect ran through oxytocin receptors. “One of them completely blocked the protective action of carbetocin when administered beforehand, showing that the benefit depends directly on the activation of the oxytocinergic system,” says Canto de Souza. But here is the twist: atosiban given on its own, at higher doses, actually prevented the anxiety too. A drug that’s supposed to be an oxytocin antagonist was producing the same result as an oxytocin agonist.

The explanation, the researchers reckon, lies in the molecular plumbing. Oxytocin receptors can couple to different signalling proteins inside the cell, mainly Gq and Gi, which trigger opposing effects. Atosiban has been reclassified in recent years as a “biased agonist” that blocks Gq signalling but activates Gi, which can release the inhibitory neurotransmitter GABA. A second, purer antagonist called L-368,899 had no effect on anxiety at any dose, which supports the idea that atosiban’s benefit comes from this quirky partial activation rather than simple blockade. It’s the kind of pharmacological wrinkle that could, eventually, matter for drug design.

When the team looked at the rats’ brains, specifically the medial prefrontal cortex, a region that helps regulate emotional responses, the picture grew more complex still. Social defeat increased oxytocin receptor levels in one subregion, the anterior cingulate cortex. But carbetocin treatment boosted receptor expression in two other subregions, the prelimbic and infralimbic cortices, and the antagonists could block that boost. Different patches of the same brain area responding to stress and to treatment in different ways; it is the sort of regional specificity that complicates any simple story about oxytocin and anxiety but also hints at why the system is so finely tuned.

There are caveats, of course, and the team is upfront about them. The study used only male rats, largely because standardised social defeat protocols for females didn’t exist when the work was designed. Given that anxiety disorders are more prevalent in women, that’s a significant gap. And the drugs were given before the stress, not after, meaning we can not yet say whether carbetocin could treat existing anxiety rather than just prevent it. “The study is further evidence of the relationship between oxytocin and this type of anxiety,” says Canto de Souza. “However… it represents an initial step in biological understanding. For it to actually become a drug for this purpose, many more studies are needed before any responsible clinical application.”

Still, the notion that you could pharmacologically armour the brain’s social-emotional circuitry against the damage of chronic bullying, not by making an animal braver but by stopping the stress from rewriting its neural responses, is worth sitting with. The oxytocin system, it seems, does not just help us bond with others. It might also help us survive what others do to us.

Study link: